Federal health preparedness agency adds to existing agreement with Emergent BioSolutions for the only FDA-approved heptavalent botulinum antitoxin
Botulinum toxin ranks among the most lethal substances known, and the threat of its deliberate use as a bioweapon has long been a concern for national security planners. To bolster its medical countermeasure reserves against that risk, a federal health agency has expanded its procurement of the primary treatment available for botulism exposure.
The Administration for Strategic Preparedness and Response (ASPR), a division of the U.S. Department of Health and Human Services, has issued a $64.5 million contract modification to Gaithersburg, Maryland-based Emergent BioSolutions for BAT (Botulism Antitoxin Heptavalent), an equine-derived antitoxin indicated for the treatment of symptomatic botulism in adults and pediatric patients. The modification extends an existing 10-year contract (75A50119C00075) under which Emergent supplies BAT to the U.S. government for stockpiling purposes.
BAT is formulated to address all seven known serotypes of botulinum neurotoxin — A through G — making it the broadest-spectrum treatment option currently available. Its indication covers both naturally occurring botulism and exposure resulting from suspected or confirmed deliberate release. The U.S. Food and Drug Administration approved the product based on animal efficacy data, as human trials for a toxin of this lethality are not ethically feasible.
For public health security practitioners and policymakers, the procurement is significant on several levels. Botulinum neurotoxin is classified as a Tier 1 select agent by the Centers for Disease Control and Prevention, reflecting the highest level of concern for potential bioterrorism misuse. Maintaining an adequate national stockpile of BAT ensures that medical responders would have a treatment option available in the event of a mass casualty incident, whether stemming from an intentional attack or a large-scale foodborne outbreak. The contract also underscores the ongoing federal commitment to sustaining domestic and North American supply chains for critical medical countermeasures, an issue that gained heightened attention following supply chain vulnerabilities exposed during the COVID-19 pandemic.
Emergent states that its manufacturing network operates within USMCA-compliant facilities, meaning production capacity is maintained across the United States, Canada, and Mexico. The company has historically served as a primary supplier of government-stockpiled countermeasures for threats including anthrax, smallpox, and Ebola, in addition to botulism.
Clinicians and formulary decision-makers should note that BAT carries several important precautions. Because it is derived from equine plasma, it carries risks of hypersensitivity reactions, including anaphylaxis and delayed serum sickness. Infusion reactions have also been observed, and the product may theoretically transmit infectious agents present in animal plasma. Common adverse reactions reported in clinical studies included fever, rash, chills, nausea, and edema. One case of hemodynamic instability was reported in a clinical study participant.
Sources and Further Reading:
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy – Emergent BioSolutions